awmsg logo



rituximab (MabThera®)


Reference No. 1048

Publication date:
13/01/2015


Appraisal information

rituximab (MabThera®) 1,400 mg subcutaneous injection


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/10/2014
AWMSG meeting date: 12/11/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 3414
Ministerial ratification: 09/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Rituximab (MabThera®) solution for subcutaneous injection is recommended as an option for use within NHS Wales for the treatment of adults for non-Hodgkin's lymphoma (NHL): for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy; and for the treatment of patients with CD20-positive diffuse large B cell NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download